Comprehensive molecular characterization of gastric adenocarcinomaAdam J. Bass, Karen Mungall, Natalie Tasman et al.|Nature|2014Cited by 6.5k
Tumor mutational load predicts survival after immunotherapy across multiple cancer typesRobert Samstein, Ronald P. DeMatteo, Chung‐Han Lee et al.|Nature Genetics|2019Cited by 4.4k
OncoKB: A Precision Oncology Knowledge BaseDebyani Chakravarty, Nikolaus Schultz, Jianjiong Gao et al.|JCO Precision Oncology|2017Cited by 2.7k
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancerYelena Y. Janjigian, Hyun Cheol Chung, Akihito Kawazoe et al.|Nature|2021Cited by 687
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trialYelena Y. Janjigian, Sun Young Rha, Patricio Yañez et al.|The Lancet|2023Cited by 461